Glutamine for the Treatment of Patients With Irritable Bowel Syndrome

• Status: Completed
• Trial end date: 2015-12-30
• Target enrollment: 0
• Participant gender: All

Summary

New and effective treatments are needed for patients with post-infectious irritable bowel syndrome (PI-IBS). We conducted a randomized, placebo-controlled trial to assess the efficacy and safety of glutamine, an abundant amino acid in the body and the principal fuel for enterocytes, in patients who developed diarrhea-predominant irritable bowel syndrome with increased intestinal permeability following an enteric infection.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Medical Branch, Galveston; Tulane University

Criteria

Inclusion Criteria:

• men and women age 18-72 years old who developed post-infectious diarrhea-predominant IBS (D-IBS)

• increased intestinal permeability on Lactulose/Mannitol permeability test

• able and willing to cooperate with the study

• *absence of alcohol or NSAIDs ingestion for 2 weeks prior to inclusion into study and throughout the study duration

Exclusion Criteria:

• current participation in another research protocol or unable to give informed consent

• women with a positive urine pregnancy test or breastfeeding

• history of inflammatory bowel disease, lactose intolerance, and/or celiac sprue

• + hydrogen breath test for bacterial overgrowth

• + antiendomysial antibody titer

• use of nonsteroidal antinflammatory drug(NSAIDs) 2 weeks before or during the study

• known allergy to glutamine

• abdominal surgery except for removal of gallbladder, uterus, or appendix

• Abnormal blood urea nitrogen(BUN) and/or creatinine